Naphazoline

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Naphazoline
Naphazoline.svg
Naphazoline.png
Clinical data
Trade namesNaphcon-a
AHFS/Drugs.comMonograph
Routes of
administration
Topical (solution)
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard100.011.492 Edit this at Wikidata
Chemical and physical data
FormulaC14H14N2
Molar mass210.274 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Naphazoline is a medicine used as a decongestant. It is a sympathomimetic agent with marked alpha adrenergic activity. It is a vasoconstrictor with a rapid action in reducing swelling when applied to mucous membrane. It acts on alpha-receptors in the arterioles of the conjunctiva to produce constriction, resulting in decreased congestion.

It was patented in 1934 and came into medical use in 1942.[1]

Chemistry[edit]

The non-hydrochloride form of Naphazoline has the molecular formula C14H14N2 and a molar mass of 210.28 g/mol. The HCl salt form has a molar mass of 246.73 g/mol.

Side effects[edit]

A few warnings and contraindications that apply to all naphazoline-containing substances intended for medicinal use are:

A possible association with stroke has been suggested.[2]

Brand names[edit]

It is an active ingredient in several over-the-counter formulations including Rohto, Eucool, Clear Eyes and Naphcon eye drops.[3]

References[edit]

  1. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 552. ISBN 9783527607495.
  2. ^ Zavala, J. A.; Pereira, E. R.; Zétola, V. H.; Teive, H. A.; Nóvak, E. M.; Werneck, L. C. (2004). "Hemorrhagic stroke after naphazoline exposition: case report". Arquivos de Neuro-Psiquiatria. 62 (3B): 889–891. doi:10.1590/S0004-282X2004000500030. PMID 15476091.
  3. ^ Green, S. M. (2008). "Ophthalmology: Naphazoline". Tarascon Pocket Pharmacopoeia 2009. Jones and Bartlett. ISBN 0-7637-6572-4.